The case for & against
Bull & Bear analysis
Bearish
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a biotechnology company dedicated to developing innovative therapies for chronic liver diseases, with a specific focus on non-alcoholic steatohepatitis (NASH) and fibrosis. The company's lead candidate, Aramcol, aims to address significant unmet medical needs associated with liver disorders and chronic inflammation. Galmed has recently broadened its pipeline by exploring treatment options in the inflammatory bowel disease (IBD) space, signifying its commitment to being a key player in therapeutics related to chronic inflammatory conditions.
Bull says
- ↑Preliminary data show 60%+ of patients achieved ≥1-stage fibrosis reduction vs 13–30% placebo
- ↑FDA clearance for Aramcol Megalomine Phase III R-MO trial accelerates approval discussions
- ↑Q4 net loss of $7.5 M offset by $34.9 M cash, supporting near-term trials
- ↑Focus on high-risk NASH (F3/F4) patients taps large unmet market opportunity
- ↑Once-daily Aramcol Megalomine dosing boosts convenience and patient adherence
- ↑Favorable book-to-price, strong liquidity, and high dividend yield underscore value upside
Bear says
- ↓Q4 net loss widened to $7.5 M and cash fell from $51 M to $34.9 M, raising funding concerns
- ↓80–90% screen failure rate in NASH trials delays enrollment and increases costs
- ↓Heavy reliance on pivotal trial success amid NASH skepticism risks share performance
- ↓Negative profitability metrics and high leverage suggest impending funding challenges
- ↓Short interest elevated at ~2.3%, reflecting strong market skepticism
- ↓Continued cash burn could force dilutive financing, pressuring equity value
Earnings Call · Q1 2021 · Mgmt. Guidance
Updated 06-29-2026neutral
Transcript signals
Bull points
- Based on our plans and the rapid regulatory approvals, I can reconfirm that results from approximately one-third of the study population, i.e., about 50 subjects, that have completed the post-baseline labor biopsy are expected to be available in Q4 2021
- We view the approval of the Aramcol study in China as a significant milestone in the development of Aramcol for national fibrosis, which may accelerate the pace of randomization of patients with the double-blind part of the ARMO study, and also position Aramcol as one of the foremost therapeutic candidates for national fibrosis in this large and emerging market.
- Topline data is expected in the second half of 2021.
Bear points
- $8.9 million, or $0.38 per share, compared with a net loss of $6.1 million, or $0.29 per share, for the corresponding quarter in 2020.
- Research and development expenses totaled $7.4 million for the first quarter of 2021, compared with $5.6 million for the first quarter in 2020.
- G&A, our general and administrative expenses for the quarter totaled $1.7 million compared with $0.9 million for the corresponding period in 2020.
Read full transcript analysis ›